Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/103730
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Deciphering the divergent roles of progestogens in breast cancer |
Author: | Carroll, J.S. Hickey, T.E. Tarulli, G.A. Williams, M. Tilley, W.D. |
Citation: | Nature Reviews Cancer, 2017; 17(1):54-64 |
Publisher: | Nature Publishing Group |
Issue Date: | 2017 |
ISSN: | 1474-175X 1474-1768 |
Statement of Responsibility: | Jason S. Carroll, Theresa E. Hickey, Gerard A. Tarulli, Michael Williams and Wayne D. Tilley |
Abstract: | Most breast cancers are driven by oestrogen receptor‑α. Anti-oestrogenic drugs are the standard treatment for these breast cancers; however, treatment resistance is common, necessitating new therapeutic strategies. Recent preclinical and historical clinical studies support the use of progestogens to activate the progesterone receptor (PR) in breast cancers. However, widespread controversy exists regarding the role of progestogens in this disease, hindering the clinical implementation of PR‑targeted therapies. Herein, we present and discuss data at the root of this controversy and clarify the confusion and misinterpretations that have consequently arisen. We then present our view on how progestogens may be safely and effectively used in treating breast cancer. |
Keywords: | Humans Breast Neoplasms Estrogen Receptor alpha Receptors, Progesterone Progestins Female |
Rights: | © 2016 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. |
DOI: | 10.1038/nrc.2016.116 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1008349 http://purl.org/au-research/grants/nhmrc/1084416 |
Published version: | http://dx.doi.org/10.1038/nrc.2016.116 |
Appears in Collections: | Aurora harvest 3 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.